Rallybio Corp

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California. “With our.

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of pat.

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody,” in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometr.

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL. A live webcast of the fireside chat will be accessible t.

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place.

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for.

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported third quarter financial results for the period ended September 30, 2024, and provided an update on recent company developments. “Advancing RLYB212 into a Phase 2 trial marks a significant achievement for Rallybio. With clinical trial application (CTA) approvals in-h.

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the approval of its clinical trial applications (CTAs) for a Phase 2 clinical trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). With these approvals from the European Medicines.

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 2.

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics.

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the NORD Rare Diseases & Orphan Pro.

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life Sciences and Fierce Healthcare has named Rallybio an Innovation Honoree as part of the 2024 Fierce 50 list. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation, and shaping the future of bioph.

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that data from the Phase 1 proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of maternal alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT), were published in Thrombosis and Haemost.

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Ascent Industries Co

DULUTH, Ga.--(BUSINESS WIRE)--National Vision, Inc., one of the largest optical retail companies in the U.S., released its 2023 Sustainability Report, “A World Worth Seeing.” The report reflects continued progress across its Social, Employees, Environment and Governance (SEE+G) framework. “In 2023, National Vision helped nearly 10 million people see better and live better. Our success as a business is deeply intertwined with our commitment to improving lives through accessible and affordable ey.

National Vision Releases 2023 Sustainability Report

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET. H.C. Wainwright.

Rallybio to Present at Upcoming Investor Conferences

Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?

LAVA Therapeutics NV

Milestone Pharmaceuticals Inc

Turnstone Biologics Corp

Are you looking for stocks to buy with low price tags?

4 Stocks Under $5 To Buy Now

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported second quarter financial results for the period ended June 30, 2024, and provided an update on recent company developments. “We are working expeditiously towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pregnant women at higher risk of fe.

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at the 2024 Jones Healthcare Seaside Summit on July 15, 2024 at 8:00 a.m. PT (11:00 a.m. ET) in Encinitas, CA. A live webcast of the presentation will be accessible through.

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in diverse ancestries. Data from this analysis confirmed Caucasian populations as having the greatest p.

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Ginkgo Bioworks Holdings

Moderna

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut.

3 Sorry Biotech Stocks to Sell in May While You Still Can

Sanofi

Although 5% up over one year, the S&P Biotechnology Select Industry Index is down .22% year-to-date. This seems to be a normalization period.

3 Biotech Stocks to Sell in May Before They Crash & Burn

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2024 and provided an update on recent company developments. “This year is off to a strong start as we continue to progress towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pre.

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m. ET in New York, NY. A live webcast of the fireside chat wil.

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a fetal and neonatal alloimmune thrombocytopenia (FNAIT) systematic literature review and meta-analysis at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, which is taking place in New Orlea.

News for Rallybio Corp Stock (RLYB)